Allergan Inc. said Monday that it again extended its $3.2 billion buyout offer for Inamed Corp. for two more weeks after federal antitrust approval was delayed.
The Irvine-based drug maker’s offer was set to expire tomorrow. It now is set to end Feb. 22. Allergan previously extended the offer in late January amid its wait for regulatory approval.
Santa Barbara-based Inamed makes breast implants, obesity treatments and face fillers.
The company said slightly more than half of Inamed’s shares had been offered to Allergan as of late last week.
Allergan officials said the companies are working with the Federal Trade Commission to complete Inamed’s sale of Reloxin. The treatment is a potential competitor to Allergan’s flagship Botox wrinkle-fighting drug.
Antitrust clearance is the last hurdle to complete the deal, Allergan said.
In an earlier interview, Allergan Chief Executive David E.I. Pyott said Inamed would return the rights to Reloxin to France’s Beaufor Ipsen SA, which developed the treatment.
